Scribe Therapeutics Inc. (NASDAQ:SCTX – Get Free Report) Director Carl Gordon bought 1,000,000 shares of the stock in a transaction dated Monday, July 27th. The stock was bought at an average price of $15.00 per share, for a total transaction of $15,000,000.00. Following the purchase, the director directly owned 1,348,825 shares of the company’s stock, valued at approximately $20,232,375. The trade was a 286.68% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Scribe Therapeutics Stock Up 1.7%
Scribe Therapeutics stock traded up $0.30 during midday trading on Wednesday, hitting $18.36. 325,049 shares of the company were exchanged, compared to its average volume of 390,915. Scribe Therapeutics Inc. has a fifty-two week low of $17.31 and a fifty-two week high of $25.49.
Further Reading
- Five stocks we like better than Scribe Therapeutics
- Why SK hynix Could Be the Best AI Chip Stock to Buy Now
- Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters
- Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?
- Why Bloom Energy May Be the Most Important AI Infrastructure Stock
Receive News & Ratings for Scribe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scribe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
